GSK’s sJNDA for Nucala to treat rhinosinusitis has been accepted for review in Japan. Credit: GSK.

The Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted GSK’s supplementary new drug application (sJNDA) for Nucala (mepolizumab), to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, for review.

Nucala is a monoclonal antibody designed to target and bind to interleukin-5 (IL-5), a cytokine that assists in the maturation and activation of eosinophils.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The sJNDA was submitted based on data from the pivotal Phase III MERIT study, which assessed the safety and efficacy of mepolizumab for more than 52 weeks in Russian, Chinese and Japanese patients with inadequately controlled CRSwNP or eosinophilic chronic rhinosinusitis.

It is also based on data from the global Phase III SYNAPSE study, which evaluated the effect of mepolizumab against placebo in more than 400 patients with CRSwNP.

If mepolizumab is approved, it is expected to become the first anti-IL-5 biologic for adults with inadequately controlled CRSwNP in Japan.

See Also:

In Japan, mepolizumab already received approval to treat bronchial asthma in children aged six years or above and in adults with refractory asthma whose symptoms could not be controlled adequately with standard treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, it was approved to treat adult patients with eosinophilic granulomatosis with polyangiitis. They have an inadequate response to the current treatment.

In 2015, Nucala was first approved to treat eosinophilic asthma in the US.

Mepolizumab has been developed to treat several IL-5-mediated diseases detected by increased eosinophil counts. It was studied in more than 4,000 patients in 41 clinical trials across various indications.